In this issue:
- Guselkumab + golimumab combination therapy in UC
- Dose escalation patterns of advanced therapies in CD and UC
- Induction with calcineurin inhibitors with ustekinumab for acute severe UC
- Induction with calcineurin inhibitors + vedolizumab for refractory UC
- TMIGD1 association with colitis and intestinal barrier dysfunction in CD
- Gut microbiome composition is associated with future onset of CD
- Ustekinumab or vedolizumab and immunomodulator combination therapy in IBD
- Real-world experience with SC infliximab
- Outcomes of a comprehensive specialist IBD nursing service
- Science blog: Microbial biofilms and IBD
Please login below to download this issue (PDF)